NZ596617A - Melanocortin receptor-specific peptides - Google Patents
Melanocortin receptor-specific peptidesInfo
- Publication number
- NZ596617A NZ596617A NZ596617A NZ59661710A NZ596617A NZ 596617 A NZ596617 A NZ 596617A NZ 596617 A NZ596617 A NZ 596617A NZ 59661710 A NZ59661710 A NZ 59661710A NZ 596617 A NZ596617 A NZ 596617A
- Authority
- NZ
- New Zealand
- Prior art keywords
- arg
- lys
- cyclo
- trp
- phe
- Prior art date
Links
- 102000004378 Melanocortin Receptors Human genes 0.000 title abstract 4
- 108090000950 Melanocortin Receptors Proteins 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 102000001189 Cyclic Peptides Human genes 0.000 abstract 3
- 108010069514 Cyclic Peptides Proteins 0.000 abstract 3
- 102100023724 Melanocortin receptor 4 Human genes 0.000 abstract 2
- 101710085775 Melanocortin receptor 4 Proteins 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- NTQDELBZOMWXRS-IWGUZYHVSA-N Asp-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O NTQDELBZOMWXRS-IWGUZYHVSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001856 erectile effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
- C07K14/685—Alpha-melanotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18492909P | 2009-06-08 | 2009-06-08 | |
| PCT/US2010/037589 WO2010144344A2 (en) | 2009-06-08 | 2010-06-07 | Melanocortin receptor-specific peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ596617A true NZ596617A (en) | 2014-04-30 |
Family
ID=43309425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ596617A NZ596617A (en) | 2009-06-08 | 2010-06-07 | Melanocortin receptor-specific peptides |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US8846601B2 (enExample) |
| EP (1) | EP2440227B1 (enExample) |
| JP (1) | JP5805632B2 (enExample) |
| KR (1) | KR101726893B1 (enExample) |
| CN (2) | CN102458436B (enExample) |
| AU (1) | AU2010259008C1 (enExample) |
| BR (1) | BRPI1009644B1 (enExample) |
| CA (1) | CA2761607C (enExample) |
| EA (1) | EA020959B1 (enExample) |
| IL (1) | IL216843A (enExample) |
| MX (1) | MX2011013117A (enExample) |
| NZ (1) | NZ596617A (enExample) |
| WO (1) | WO2010144344A2 (enExample) |
| ZA (1) | ZA201200112B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ596617A (en) * | 2009-06-08 | 2014-04-30 | Palatin Technologies Inc | Melanocortin receptor-specific peptides |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| NZ599774A (en) | 2009-11-23 | 2014-11-28 | Palatin Technologies Inc | Melanocortin-1 receptor-specific cyclic peptides |
| WO2012100342A1 (en) | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| ES2732077T3 (es) | 2011-12-29 | 2019-11-20 | Rhythm Pharmaceuticals Inc | Método para tratar trastornos asociados con el receptor de melanocortina-4 en portadores heterocigotos |
| US9284283B2 (en) | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
| EP2970389B1 (en) | 2013-03-15 | 2020-08-19 | Rhythm Pharmaceuticals, Inc. | Pharmaceutical compositions |
| CN118240012A (zh) * | 2013-03-15 | 2024-06-25 | 节奏制药公司 | 肽组合物 |
| US10174078B2 (en) * | 2014-04-25 | 2019-01-08 | Phi Pharma Sa | Keratan sulfate specific transporter molecules |
| CN104436159A (zh) * | 2014-12-09 | 2015-03-25 | 天津医科大学眼科医院 | 一种新型滴眼液对治疗干眼的用途 |
| WO2016168388A2 (en) * | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| ES2985734T3 (es) | 2015-09-30 | 2024-11-07 | Rhythm Pharmaceuticals Inc | Método de tratamiento de trastornos asociados a la vía del receptor de la melanocortina-4 |
| JP2019535702A (ja) * | 2016-11-09 | 2019-12-12 | ナンヤン テクノロジカル ユニヴァーシティー | ジンセンチド及びジンセンチド様ペプチドの調製及び使用 |
| EP3768245A4 (en) * | 2018-03-23 | 2023-10-18 | Palatin Technologies, Inc. | MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDE FORMULATIONS AND METHODS FOR GASTROINTESTINAL TRACT-SPECIFIC ADMINISTRATION |
| AU2019249255A1 (en) | 2018-04-06 | 2020-11-05 | Alastair GARFIELD | Compositions for treating kidney disease |
| CN115279390A (zh) * | 2020-02-03 | 2022-11-01 | 帕拉丁科技公司 | 反向酰胺连接的促黑素受体特异性环状肽 |
| EP4100040A4 (en) * | 2020-02-03 | 2024-06-05 | Palatin Technologies, Inc. | DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES |
| CN114890958B (zh) * | 2022-02-23 | 2023-10-20 | 四川警察学院 | 双光子染料化合物、其制备方法及其应用 |
| CN115521356B (zh) * | 2022-08-17 | 2024-04-02 | 桂林医学院 | 一种具有美白功效的多肽及其应用 |
| CN119529031B (zh) * | 2024-11-27 | 2025-12-05 | 润辉生物技术（威海）有限公司 | 一种环肽衍生物及其制备方法与应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| JP3219096B2 (ja) | 1990-05-10 | 2001-10-15 | ニコメド ファーマ エイエス | ｎ―グリコフロール類及びｎ―エチレングリコール類を含有する医薬製剤 |
| US6100048A (en) | 1992-04-10 | 2000-08-08 | Oregon Health Sciences University | Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals |
| US5977070A (en) | 1992-07-14 | 1999-11-02 | Piazza; Christin Teresa | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
| US6054556A (en) | 1995-04-10 | 2000-04-25 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Melanocortin receptor antagonists and agonists |
| US5731408A (en) | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
| US7396814B2 (en) | 1995-06-07 | 2008-07-08 | Palatin Technologies, Inc. | Metallopeptide compositions for treatment of sexual dysfunction |
| JP2001506996A (ja) | 1996-12-17 | 2001-05-29 | クアドラント ホールディングス ケンブリッジ リミテッド | メラノコルチン受容体３、４又は５の特異結合のためのメラノコルチン誘導体 |
| PT949905E (pt) | 1996-12-20 | 2001-12-28 | Alza Corp | Composicao de gel injectavel de efeito retardado e processo para a sua preparacao |
| US5908825A (en) | 1997-01-09 | 1999-06-01 | University Of Maryland At Baltimore | Dosage composition for nasal delivery and method of use of the same |
| WO1999021571A1 (en) | 1997-10-27 | 1999-05-06 | Trega Biosciences, Inc. | Melanocortin receptor ligands and methods of using same |
| US6193991B1 (en) | 1997-10-29 | 2001-02-27 | Atul J. Shukla | Biodegradable delivery systems of biologically active substances |
| GB9808229D0 (en) | 1998-04-17 | 1998-06-17 | Quadrant Holdings Cambridge | Melanocortin receptor ligands |
| SE9801571D0 (sv) | 1998-05-05 | 1998-05-05 | Wapharm Ab | Melanokortin-1-receptorselektiva föreningar |
| GB9816234D0 (en) | 1998-07-24 | 1998-09-23 | William Harvey Research Limite | Compounds for use in the treatment of inflammation |
| GB9827500D0 (en) | 1998-12-14 | 1999-02-10 | Wapharm Ab | Compounds for control of eating, growth and body weight |
| US6887846B2 (en) | 1999-03-24 | 2005-05-03 | Zengen, Inc. | Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone |
| CA2368431C (en) | 1999-03-29 | 2006-01-24 | The Procter & Gamble Company | Melanocortin receptor ligands |
| US7176279B2 (en) | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
| US6579968B1 (en) * | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
| US7235625B2 (en) * | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
| US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
| WO2001030808A1 (en) | 1999-10-27 | 2001-05-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor-ligand binding |
| JP2003534240A (ja) | 2000-01-18 | 2003-11-18 | メルク エンド カムパニー インコーポレーテッド | 強力な選択的メラノコルチン−４受容体アンタゴニストとなる環状ペプチド |
| US6600015B2 (en) | 2000-04-04 | 2003-07-29 | Hoffmann-La Roche Inc. | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity |
| WO2001085930A2 (en) | 2000-05-09 | 2001-11-15 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
| GB0012370D0 (en) | 2000-05-22 | 2000-07-12 | Quadrant Holdings Cambridge | Peptoids |
| DK1315750T3 (da) | 2000-08-30 | 2007-06-11 | Hoffmann La Roche | Cykliske peptider med melanocortin-4-receptoragonistaktivitet |
| CN1571796A (zh) | 2000-09-27 | 2005-01-26 | 宝洁公司 | 黑皮素受体配体 |
| US7345144B2 (en) * | 2001-07-11 | 2008-03-18 | Palatin Technologies, Inc. | Cyclic peptides for treatment of cachexia |
| US7342089B2 (en) | 2001-07-11 | 2008-03-11 | Palatin Technologies, Inc. | Cyclic peptides for treatment for cachexia |
| EP1441750A4 (en) | 2001-07-11 | 2006-10-18 | Palatin Technologies Inc | LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR |
| CA2453027A1 (en) | 2001-07-12 | 2003-01-23 | Merck & Co., Inc. | Cyclic peptides as potent and selective melanocortin-4 receptor agonists |
| FR2835528B1 (fr) | 2002-02-01 | 2004-03-12 | Inst Europ Biolog Cellulaire | Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique |
| US7034004B2 (en) | 2002-05-07 | 2006-04-25 | University Of Florida | Peptides and methods for the control of obesity |
| AU2003248888A1 (en) | 2002-07-09 | 2004-01-23 | Palatin Technologies, Inc. | Peptide composition for treatment of sexual dysfunction |
| AU2003290886A1 (en) | 2002-11-14 | 2004-06-15 | Zengen, Inc. | Modified alpha-msh peptides and derivatives thereof |
| US7135548B2 (en) | 2002-11-14 | 2006-11-14 | Zengen, Inc. | Modified α-MSH peptides and derivatives thereof |
| US7183255B2 (en) | 2003-02-26 | 2007-02-27 | Intradialytic Pharmaceuticals | Method for stabilizing blood pressure in hemodialysis subjects |
| WO2004099246A2 (en) | 2003-05-09 | 2004-11-18 | Novo Nordisk A/S | Peptides for use in treating obesity |
| KR20060026011A (ko) | 2003-05-09 | 2006-03-22 | 노보 노르디스크 에이/에스 | 비만 치료용 펩티드 |
| CN1809372A (zh) * | 2003-06-19 | 2006-07-26 | 伊莱利利公司 | 黑皮质素受体4(mc4)激动剂及其用途 |
| US20060293223A1 (en) | 2003-06-19 | 2006-12-28 | Eli Lilly And Company Patent Division | Uses of melanocortin-3 receptor (mc3r) agonist peptides |
| JP2006527773A (ja) * | 2003-06-19 | 2006-12-07 | イーライ リリー アンド カンパニー | メラノコルチン受容体４（ｍｃ４）作用薬とその用途 |
| US7084111B2 (en) | 2003-06-23 | 2006-08-01 | University Of Florida Research Foundation, Inc. | Melanocortin receptor templates, peptides, and use thereof |
| US20070293423A1 (en) | 2003-08-20 | 2007-12-20 | Eli Lilly And Company | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide |
| WO2005030797A2 (en) | 2003-09-30 | 2005-04-07 | Novo Nordisk A/S | Melanocortin receptor agonists |
| WO2005048967A1 (en) | 2003-11-24 | 2005-06-02 | Clinuvel Pharmaceuticals Limited | A method of inducing melanogenesis in humans with mc1r variant alleles |
| EP1694348A4 (en) | 2003-12-10 | 2009-07-01 | Merck & Co Inc | INHIBITION OF VOLUNTARY ETHANOL CONSUMPTION WITH SELECTIVE MELANOCORTIN-4-RECEPTOR AGONISTS |
| JP2007530674A (ja) | 2004-03-29 | 2007-11-01 | イーライ リリー アンド カンパニー | 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用 |
| ES2566801T3 (es) | 2004-08-04 | 2016-04-15 | Clinuvel Pharmaceuticals Limited | Métodos de inducción de melanogénesis en un sujeto |
| ME01234B (me) | 2004-10-25 | 2013-06-20 | Centocor Inc | Mimetička tijela koja vezuju receptore melanokortina, smjese, postupci i upotrebe |
| US20080306008A1 (en) | 2004-11-04 | 2008-12-11 | Nova Nordisk A/S | Peptides for Use in the Treatment of Obesity |
| JP2008519009A (ja) | 2004-11-04 | 2008-06-05 | ノボ ノルディスク アクティーゼルスカブ | 肥満症の治療に使用するためのペプチド |
| US20110098213A1 (en) | 2004-11-04 | 2011-04-28 | Novo Nordisk A/S | Novel peptides for use in the treatment of obesity |
| JP2008519006A (ja) | 2004-11-04 | 2008-06-05 | ノボ ノルディスク アクティーゼルスカブ | 肥満症の治療に使用するためのペプチド |
| EP1863841A1 (en) | 2005-03-17 | 2007-12-12 | Novo Nordisk A/S | Compounds for use in the treatment of obesity |
| EP2548568B1 (en) | 2005-07-08 | 2018-01-10 | Ipsen Pharma | Melanocortin receptor ligands |
| RU2401841C2 (ru) | 2005-07-08 | 2010-10-20 | Ипсен Фарма С.А.С. | Лиганды рецепторов меланокортинов |
| RU2008100218A (ru) | 2005-07-18 | 2009-08-27 | Ново Нордикс А/С (Dk) | Пептиды для лечения ожирения |
| EP1957096A4 (en) | 2005-08-29 | 2012-03-21 | Palatin Technologies Inc | CYCLIC PEPTIDE INSULATION BY SPRAY DRYING |
| US8114844B2 (en) * | 2006-03-30 | 2012-02-14 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptidomimetics |
| SI2056855T1 (sl) | 2006-08-31 | 2015-01-30 | Clinuvel Pharmaceuticals Limited | Alfa-msh derivati za zdravljenje fotodermazoze |
| CN101177450A (zh) * | 2006-11-09 | 2008-05-14 | 武汉聚奇医药科技有限公司 | 引发男性阴茎勃起和提高女性性欲的短肽 |
| EP2104684A1 (en) | 2007-01-18 | 2009-09-30 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
| EP2101822A2 (en) | 2007-01-18 | 2009-09-23 | Novo Nordisk A/S | Use of peptides in combination with surgical intervention for the treatment of obesity |
| US20100056433A1 (en) | 2007-01-18 | 2010-03-04 | Novo Nordisk A/S | Novel Peptides for Use in the Treatment of Obesity |
| WO2008087186A2 (en) | 2007-01-18 | 2008-07-24 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
| CN101302246B (zh) * | 2007-05-09 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 黑色素皮质激素受体七肽类激动剂及其制备方法和用途 |
| TW200848424A (en) | 2007-06-15 | 2008-12-16 | Sod Conseils Rech Applic | Cyclic peptide melanocortin receptor ligands |
| CN103316345B (zh) | 2007-11-05 | 2016-05-18 | 益普生制药股份有限公司 | 黑皮质素治疗胰岛素敏感的应用 |
| EP2300036B1 (en) * | 2008-06-09 | 2017-04-05 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for treatment of sexual dysfunction |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| NZ596617A (en) * | 2009-06-08 | 2014-04-30 | Palatin Technologies Inc | Melanocortin receptor-specific peptides |
-
2010
- 2010-06-07 NZ NZ596617A patent/NZ596617A/en unknown
- 2010-06-07 EA EA201190338A patent/EA020959B1/ru not_active IP Right Cessation
- 2010-06-07 AU AU2010259008A patent/AU2010259008C1/en not_active Ceased
- 2010-06-07 BR BRPI1009644-2A patent/BRPI1009644B1/pt active IP Right Grant
- 2010-06-07 CA CA2761607A patent/CA2761607C/en active Active
- 2010-06-07 CN CN201080024349.9A patent/CN102458436B/zh active Active
- 2010-06-07 KR KR1020127000543A patent/KR101726893B1/ko active Active
- 2010-06-07 MX MX2011013117A patent/MX2011013117A/es active IP Right Grant
- 2010-06-07 JP JP2012514221A patent/JP5805632B2/ja active Active
- 2010-06-07 CN CN201510295826.XA patent/CN105037502A/zh active Pending
- 2010-06-07 EP EP10786619.6A patent/EP2440227B1/en active Active
- 2010-06-07 WO PCT/US2010/037589 patent/WO2010144344A2/en not_active Ceased
-
2011
- 2011-12-06 US US13/311,824 patent/US8846601B2/en active Active
- 2011-12-08 IL IL216843A patent/IL216843A/en active IP Right Grant
-
2012
- 2012-01-07 ZA ZA2012/00112A patent/ZA201200112B/en unknown
-
2014
- 2014-07-11 US US14/328,995 patent/US9458201B2/en active Active
-
2016
- 2016-07-20 US US15/214,845 patent/US10179804B2/en active Active
-
2019
- 2019-01-11 US US16/245,735 patent/US10632171B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ596617A (en) | Melanocortin receptor-specific peptides | |
| MX2012005859A (es) | Peptidos lineales especificos del receptor de melanocortina-1. | |
| NZ599774A (en) | Melanocortin-1 receptor-specific cyclic peptides | |
| BRPI0923786C8 (pt) | compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos | |
| MX2012001194A (es) | Peptidos tau antigenicos y usos de los mismos. | |
| MY153258A (en) | Pyrazinone derivatives and their use inthe threatment of lung diseases | |
| BR112012010253A8 (pt) | compostos de pirimidina como moduladores do receptor delta opioide | |
| MX2010008749A (es) | Inhibidores del virus de la hepatitis c. | |
| NZ603901A (en) | Vectors and sequences for the treatment of diseases | |
| BR112013033182A2 (pt) | compostos imidazopiridinil-aminopiridina substituída | |
| MX2010008531A (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| NZ588954A (en) | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | |
| GB0917002D0 (en) | Improved shigella blebs | |
| MX2012002366A (es) | Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina. | |
| NZ616989A (en) | Therapeutic nuclease compositions and methods | |
| JO2682B1 (en) | Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof | |
| EA201001722A1 (ru) | Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции | |
| WO2010144341A3 (en) | Lactam-bridged melanocortin receptor-specific peptides | |
| MA32544B1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique | |
| MX2010006202A (es) | Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| EA011572B9 (ru) | Производные хинолина для применения в качестве микобактериальных ингибиторов | |
| NZ610378A (en) | Lipoyl compounds and their use for treating ischemic injury | |
| JO3760B1 (ar) | (مشتقات بريجنان مكثفة في الموضع 16، 17 ذات حلقة أيزوكسازوليدين بها استبدال عند - n كعوامل مضادة للالتهاب) | |
| MX2012005225A (es) | Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso. | |
| NZ601142A (en) | Composition for improving brain function and method for improving brain function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 JUN 2017 BY CPA GLOBAL Effective date: 20140812 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2018 BY CPA GLOBAL Effective date: 20170421 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2019 BY CPA GLOBAL Effective date: 20180426 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2020 BY CPA GLOBAL Effective date: 20190425 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2021 BY CPA GLOBAL Effective date: 20200424 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2022 BY CPA GLOBAL Effective date: 20210422 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2023 BY CPA GLOBAL Effective date: 20220421 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2024 BY CPA GLOBAL Effective date: 20230420 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240425 |